Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/cells10020255 http://scihub22266oqcxt.onion/10.3390/cells10020255 33525562!7910927!33525562     free     free     free       Cells 2021 ; 10 (2): ä Nephropedia Template TP {{tp|p=33525562|t=2021. Lithium and Therapeutic Targeting of GSK-3 |pdf=|usr=}}{{33525562}} gab.com Text Lithium and Therapeutic Targeting of GSK-3 JO: Cells http://www.kidney.de/pget.php?&tw=1&pmid=33525562 #FOAvip Lithium salts have been in the therapeutic toolbox for better or worse since the 19th century, with purported benefit in gout, hangover, insomnia, and early suggestions that lithium improved psychiatric disorders. However, the remarkable effects of lithium reported by John Cade and subsequently by Mogens Schou revolutionized the treatment of bipolar disorder. The known molecular targets of lithium are surprisingly few and include the signaling kinase glycogen synthase kinase-3 (GSK-3), a group of structurally related phosphomonoesterases that includes inositol monophosphatases, and phosphoglucomutase. Here we present a brief history of the therapeutic uses of lithium and then focus on GSK-3 as a therapeutic target in diverse diseases, including bipolar disorder, cancer, and coronavirus infections. Twit Text FOAVip Lithium and Therapeutic Targeting of GSK-3 ????Cells http://www.kidney.de/pget.php?&tw=1&pmid=33525562 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33525562 #FOAvip English Wikipedia <ref>{{Cite pmid|33525562}}</ref> Lithium and Therapeutic Targeting of GSK-3 #MMPMID33525562 Snitow ME; Bhansali RS; Klein PS Cells 2021[Jan]; 10 (2): ä PMID33525562show ga Lithium salts have been in the therapeutic toolbox for better or worse since the 19th century, with purported benefit in gout, hangover, insomnia, and early suggestions that lithium improved psychiatric disorders. However, the remarkable effects of lithium reported by John Cade and subsequently by Mogens Schou revolutionized the treatment of bipolar disorder. The known molecular targets of lithium are surprisingly few and include the signaling kinase glycogen synthase kinase-3 (GSK-3), a group of structurally related phosphomonoesterases that includes inositol monophosphatases, and phosphoglucomutase. Here we present a brief history of the therapeutic uses of lithium and then focus on GSK-3 as a therapeutic target in diverse diseases, including bipolar disorder, cancer, and coronavirus infections. |Animals[MESH] |Antimanic Agents/pharmacology/*therapeutic use[MESH] |Bipolar Disorder/*drug therapy/metabolism[MESH] |Coronavirus/drug effects[MESH] |Glycogen Synthase Kinase 3/metabolism[MESH] |Humans[MESH] |Lithium Compounds/pharmacology/*therapeutic use[MESH] |Neoplasms/*drug therapy/metabolism[MESH] |Neurodegenerative Diseases/*drug therapy/metabolism[MESH] |Phosphoric Monoester Hydrolases/metabolism[MESH] |Severe Acute Respiratory Syndrome/*drug therapy/metabolism[MESH]Lithium and Therapeutic Targeting of GSK-3 (epmc).pdf DeepDyve Pubget Overpricing